澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate; purified talc; hyprolose; hypromellose; magnesium stearate; macrogol 6000; croscarmellose sodium; titanium dioxide - indicated for the treatment of hypertension. indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (greater than or equal to 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

美国 - 英文 - NLM (National Library of Medicine)

westminster pharmaceuticals, llc - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n) - irbesartan 75 mg in 75 mg - hypertension irbesartan tablets, usp is indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. nephropathy in type 2 diabetic patients irbesartan tablets, usp is indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. in this population, irbesartan tablets, usp reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end-stage renal disease (need for dialysis or renal transplantation) (see clinical pharmacology: clinical studies). irbesartan tablets, usp are contraindicated in patients who are hypersensitive to any component of this product. do not co-administer aliskiren with irbesartan tablets, usp in patients with diabetes (see precautions: drug interactions).

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan -

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan -

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan -

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan -

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan -

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan -

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: polysorbate 80; sodium starch glycollate type b; hypromellose; magnesium stearate; macrogol 6000; microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate - indicated for the treatment of hypertension.,indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: polysorbate 80; magnesium stearate; hypromellose; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type b; macrogol 6000; lactose monohydrate - indicated for the treatment of hypertension.,indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.